Compound Summary
Compound Information
Candesartan cilexetil
Compound Name: | Candesartan cilexetil |
Compound CID: | 2540 |
Synonyms: | Candesartan cilexetil 145040-37-5 Atacand TCV-116 Amias More... |
Iupac Name: | 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate |
InChI: | InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38) |
InChIKey: | GHOSNRCGJFBJIB-UHFFFAOYSA-N |
Canonical Smiles: | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6 |
Isomeric Smiles: | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6 |
Molecular Weight: | 610.7 |
Molecular Formula: | C33H34N6O6 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Candesartan cilexetil
Molecular Weight: | 610.7 |
Molecular Formula: | C33H34N6O6 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 10 |
Rotatable Bond Count: | 13 |
Heavy Atom Count: | 45 |
Complexity: | 962 |
Synonyms
Candesartan cilexetil
| Candesartan cilexetil | Candesartan cilexetil |
|---|---|
Candesartan cilexetil |
145040-37-5 |
Atacand |
TCV-116 |
Amias |
Parapres |
Kenzen |
CANDESARTAN CILEXTIL |
TCV 116 |
candesartancilexetil |
Candesartan cilexetil USAN |
NSC-758697 |
CHEMBL1014 |
CHEBI:3348 |
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2-(2H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-2-ethoxy-1H-benzodimidazole-7-carboxylate |
R85M2X0D68 |
1-(cyclohexyloxycarbonyloxy)ethyl 1-((2-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzodimidazole-7-carboxylate |
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-4-2-(2H-tetrazol-5-yl)phenylphenylmethylbenzimidazole-4-carboxylate |
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-2-ethoxy-1H-benzodimidazole-7-carboxylate |
Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester |
Candesartan 1-(cyclohexyloxy)carbonyloxyethyl ester |
Racanda |
UNII-R85M2X0D68 |
TCY 116 |
Candesartan hexetil |
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-4-2-(1H-tetrazol-5-yl)phenylphenylmethylbenzimidazole-4-carboxylate |
Atacand (TN) |
candesartan cilexitil |
MFCD00871371 |
Spectrum_001707 |
Candesartan (Cilexetil) |
Spectrum2_000485 |
Spectrum3_000996 |
Spectrum4_001124 |
Spectrum5_001462 |
Candesartan Celexetil Ester |
SCHEMBL40831 |
BSPBio_002691 |
Candesartan cilexetil- Bio-X |
KBioGR_001607 |
KBioSS_002187 |
1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2-(1H-tetrazol-5-yl)(1,1-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- |
Candesartan Cilexetil-d11 |
MLS004774127 |
Candesartan cilexetil , 97% |
SPECTRUM1504261 |
SPBio_000349 |
GTPL8352 |
Candesartan cilexetil (Atacand) |
DTXSID5020239 |
KBio2_002187 |
KBio2_004755 |
KBio2_007323 |
KBio3_001911 |
HMS1922J09 |
HMS2093E20 |
HMS3651I08 |
Pharmakon1600-01504261 |
Candesartan cilexetil (JP17/USP) |
CANDESARTAN CILEXETIL JAN |
BCP22050 |
Tox21_302202 |
AC-204 |
BDBM50318907 |
CANDESARTAN CILEXETIL VANDF |
CCG-39530 |
NSC758697 |
s2037 |
STL451065 |
CANDESARTAN CILEXETIL MART. |
AKOS015894954 |
AKOS015920180 |
CANDESARTAN CILEXETIL USP-RS |
CANDESARTAN CILEXETIL WHO-DD |
AB07617 |
AM90293 |
BCP9000480 |
CCG-222334 |
DB00796 |
DS-1302 |
KS-1147 |
NSC 758697 |
Candesartan cilexetil, >=98% (HPLC) |
NCGC00095123-01 |
NCGC00095123-02 |
NCGC00095123-03 |
NCGC00095123-05 |
NCGC00095123-10 |
NCGC00095123-16 |
NCGC00255218-01 |
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester) |
1-(cyclohexyloxy)carbonyloxyethyl 2-ethoxy-1-2-(1h-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl-1h-benzimidazole-7-carboxylate" |
1-{(cyclohexyloxy)carbonyloxy}ethyl 2-(ethyloxy)-1-{2-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-benzimidazole-7-carboxylate" |
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2-(1H-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-" |
2-ETHOXY-1-2-(2H-TETRAZOL-5-YL)1,1-BIPHENYL-4-YLMETHYL-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-(CYCLOHEXYLOXY)CARBONYLOXYETHYL ESTER" |
2-Ethoxy-3-2-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester |
BC164274 |
HY-17505 |
SMR003500784 |
CANDESARTAN CILEXETIL ORANGE BOOK |
SBI-0206767.P001 |
CANDESARTAN CILEXETIL EP MONOGRAPH |
CANDESARTAN CILEXETIL USP MONOGRAPH |
CAS-145040-37-5 |
FT-0602914 |
SW220041-1 |
C07709 |
D00626 |
EN300-118698 |
AB01274805-01 |
AB01274805_02 |
AB01274805_03 |
040C375 |
H212/91 |
L006257 |
SR-05000001976 |
Camptothecine, Antibiotic for Culture Media Use Only |
Q-200786 |
SR-05000001976-1 |
BRD-A65671304-001-02-6 |
BRD-A65671304-001-03-4 |
Q27075664 |
Z1515383338 |
CANDESARTAN 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER MI |
Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard |
Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard |
Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard |
Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard |
Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material |
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-2-(1H-tetrazol-5-yl) biphenyl-4-ylmethylbenzimidazole-7-carboxylate" |
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-2-(1H-tetrazol-5-yl)biphenyl-4-ylmethylbenzimidazole-7-carboxylate |
(+/-)-1-HYDROXYETHYL 2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLATE, CYCLOHEXYL CARBONATE (ESTER) |
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl1-((2-(2H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-2-ethoxy-1H-benzodimidazole-7-carboxylate" |
1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-2-(1H-tetrazol-5-yl)biphenyl-4-ylmethylbenzimidazol-7-carboxylate" |
1-{(cyclohexyloxy)carbonyloxy}ethyl 2-ethoxy-1-{2-(1H-1,2,3,4-tetrazol-5-yl)-1,1-biphenyl-4-ylmethyl}-1H-1,3-benzodiazole-7-carboxylate" |
1-{(cyclohexyloxy)carbonyloxy}ethyl 2-ethoxy-1-{2-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-benzimidazole-7-carboxylate |
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-4-2-(2h-tetrazol-5-yl)phenylphenyl methylbenzimidazole-4-carboxylate |
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-4-2-(2H-tetrazol-5-yl)phenylphenylmethylbenzimidazole-4-carboxylate. |
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 2-ETHOXY-1-((2-(1H-TETRAZOL-5-YL)(1,1-BIPHENYL)-4-YL)METHYL)-, 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER, (+/-)-" |
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-2-(2H-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl-, 1-(cyclohexyloxy)carbonyloxyethyl ester" |
2-Ethoxy-1-2-(1H-tetrazole-5-yl)-4-biphenylylmethyl-1H-benzimidazole-7-carboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester" |
2-Ethoxy-3-2-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester" |
2-Ethoxy-3-2-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester" |
2-ethoxy-3-2-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl-3h-benzoimidazole-4-carboxylic acid 1-cyclohe" |
Experimental Data
Candesartan cilexetil
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mus musculus | 30 | ppm | 874 | 880 | 1 | 1047 | 1120 | 7 | NS | C57BL/6 J | FEMALES | 33788371 | Inactive |
| Mus musculus | 30 | ppm | 787 | 820 | 4 | 1047 | 1055 | 1 | NS | C57BL/6 J | MALES | 33788371 | Inactive |
Experimental Data Visualization
Candesartan cilexetil
Statistics Data
Candesartan cilexetil
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Mus musculus | 4 | 7 | 1 | 2 |
Statistics Data Visualization
Candesartan cilexetil
